GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bide Pharmatech Co Ltd (SHSE:688073) » Definitions » Gross-Profit-to-Asset %

Bide Pharmatech Co (SHSE:688073) Gross-Profit-to-Asset % : 17.04% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Bide Pharmatech Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Bide Pharmatech Co's annualized Gross Profit for the quarter that ended in Mar. 2024 was ¥409 Mil. Bide Pharmatech Co's average Total Assets over the quarter that ended in Mar. 2024 was ¥2,398 Mil. Therefore, Bide Pharmatech Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 17.04%.


Bide Pharmatech Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Bide Pharmatech Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bide Pharmatech Co Gross-Profit-to-Asset % Chart

Bide Pharmatech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial 69.34 53.39 41.70 22.66 18.30

Bide Pharmatech Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.40 17.09 18.50 18.70 17.04

Competitive Comparison of Bide Pharmatech Co's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Bide Pharmatech Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bide Pharmatech Co's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bide Pharmatech Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Bide Pharmatech Co's Gross-Profit-to-Asset % falls into.



Bide Pharmatech Co Gross-Profit-to-Asset % Calculation

Bide Pharmatech Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=436.738/( (2359.206+2415.028)/ 2 )
=436.738/2387.117
=18.30 %

Bide Pharmatech Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=408.608/( (2415.028+2381.92)/ 2 )
=408.608/2398.474
=17.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Bide Pharmatech Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Bide Pharmatech Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bide Pharmatech Co (SHSE:688073) Business Description

Traded in Other Exchanges
N/A
Address
No. 128, Xiangyin Road, Room 101, Block A, Building 11, Yangpu District, Shanghai, CHN, 200433
Bide Pharmatech Co Ltd is engaged in the research and development, design, production and sales of drug molecular building blocks.
Executives
Dai Lan Director

Bide Pharmatech Co (SHSE:688073) Headlines

No Headlines